Piffanelli A, Giovannini G, Pelizzola D, De Bortoli M, Catozzi L, Giganti M
Cattedra di Medicina Nucleare, Università degli Studi, Ferrara.
Ann Ist Super Sanita. 1991;27(3):523-9.
An Italian Committee for the quality assessment of steroid receptor assay was instituted in 1979; the number of laboratories participating in this program increased from 7 in 1979 to 43 in 1989. The Italian program in collaboration with EORTC (European Organization Research and Treatment of Cancer) initiatives, utilizes as working standards lyophilized samples that tolerate prolonged storage at 4 degrees C. The national representatives agreed, according to EORTC, that all laboratories would perform, for measurement of steroid receptors, the dextran coated charcoal (DCC) method using the same concentration of radioactive ligands (3-H-estradiol, 3-H-ORG-2058) and would determine the non-specific binding with the same compounds (diethylstilbestrol and ORG-2058). The computation method is a potential source of interlaboratory variation; the multipoint Scatchard analysis, though difficult to apply for receptor problems, is the most widely used approach at present. The standardized DCC method is the most common and recognized (Food and Drug Administration) procedure for quantifying hormone receptor in human cancer. Since new technologies are being introduced (receptor enzyme immunoassay, EIA), adequate programs of quality assessment are required; in general, it has demonstrated an excellent correlation between radioligand binding assay (DCC) and immunochemical assay (EIA). Other prognostic factors, such as proteins produced by oncogenes and growth factors of the malignant cells have become more important. Some of these factors, as well as estrogen receptor status, seem the major determinants of recurrence after the first treatment.
1979年成立了一个意大利类固醇受体检测质量评估委员会;参与该项目的实验室数量从1979年的7个增加到1989年的43个。意大利的项目与欧洲癌症研究与治疗组织(EORTC)的倡议合作,使用在4摄氏度下能耐受长期储存的冻干样本作为工作标准品。根据EORTC的要求,各国代表一致同意,所有实验室在测量类固醇受体时,都应采用葡聚糖包被活性炭(DCC)法,使用相同浓度的放射性配体(3 - H - 雌二醇、3 - H - ORG - 2058),并使用相同的化合物(己烯雌酚和ORG - 2058)来测定非特异性结合。计算方法是实验室间差异的一个潜在来源;多点Scatchard分析虽然难以应用于受体问题,但却是目前使用最广泛的方法。标准化的DCC方法是目前在人类癌症中定量激素受体最常用且被认可(美国食品药品监督管理局)的程序。由于正在引入新技术(受体酶免疫测定法,EIA),因此需要适当的质量评估方案;总体而言,放射性配体结合测定法(DCC)和免疫化学测定法(EIA)之间已显示出极好的相关性。其他预后因素,如癌基因产生的蛋白质和恶性细胞的生长因子,变得更加重要。这些因素中的一些,以及雌激素受体状态,似乎是首次治疗后复发的主要决定因素。